KTTAW

Investor Moves

Name	Value	Action	Change	Price	Current Price
Ken GriffinCitadel Advisors $-207 ExitQ4 2025 $207 -- $0.0098
Ken GriffinCitadel Advisors $-128 TrimQ3 2025 $128 -- $0.0098
Ken GriffinCitadel Advisors $-144 ExitQ3 2024 $144 -- $0.0098

Insider Trades

Name	Value	Action	Price	Current Price
Steinman LawrenceDirector $100k133.3k shares BuyNov 28, 2025 $0.75 $0.0098
Dumesnil SimonDirector $25k33.3k shares BuyNov 28, 2025 $0.75 $0.0098
Marques TiagoDirector, Officer: Chief Executive Officer $25k33.3k shares BuyNov 28, 2025 $0.75 $0.0098
Marques TiagoDirector, Officer: Chief Executive Officer $792960 shares SellMay 12, 2025 $0.825 $0.0098

Trade KTTAW

About Pasithea Therapeutics Corp.

Pasithea Therapeutics Corp. is a biotechnology firm dedicated to exploring and developing therapies for various psychiatric and neurological conditions. Beyond its research endeavors, the company intends to establish clinics specializing in the treatment of depression. At these facilities, certified pharmacists will administer intravenous ketamine infusions, and the firm will also extend business support services for these operations. Founded in 2020, Pasithea Therapeutics Corp. maintains its corporate headquarters in Miami Beach, Florida.

CEO: Tiago Reis Marques
IPO Date: Sep 15, 2021

Market Data

Open: $0.0048
High: $0.0058
Low: $0.0048
Volume: 1.4K
Avg Volume: 25K
52W High: $0.0122
52W Low: $0.0048

Valuation

Market Cap: $43.2K
Enterprise Value: -$46.7M
Dividend Yield: 0.00%

Financials

Free Cash Flow: -$15.2B
Revenue: $0
Net Income: -$20.4M
Cash: $55.2M
Debt: $0

Events

EarningsSep 2

EPS est. -0.16